Hwail Pharm KRX:061250KOSDAQ
화일약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h5
Articles, 7 days5
DART filings, 7 days6
Articles tracked5since Sep 11
In Q2 2026, Hwail Pharm reported revenue of ₩24.5bn, down 12.5% year on year, and an operating loss of ₩912m. Hwail Pharm (화일약품) appeared in 5 Korean news articles and 6 DART filings over the past seven days. Coverage peaked on Sep 15 with 5 articles. The most common catalyst was stakes & m&a (1).
Filing signals Control change Swung to loss Screener
Hwail Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩24.5bn | -12.5% | −₩912m | ₩4.4bn |
| Q1 2026 | ₩23.4bn | -21.8% | −₩566m | ₩579m |
| Q4 2025 derived | ₩18.6bn | -30.3% | −₩1.3bn | −₩516m |
| Q3 2025 | ₩24.3bn | -17.9% | ₩165m | ₩388m |
| Q2 2025 | ₩28.0bn | -11.6% | ₩51m | ₩551m |
| Q1 2025 | ₩30.0bn | -6.0% | −₩1.2bn | −₩657m |
| Q4 2024 derived | ₩26.6bn | -9.2% | −₩411m | ₩5.8bn |
| Q3 2024 | ₩29.6bn | +3.1% | ₩140m | ₩79m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Hwail Pharm top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Hwail Pharm news Korean headlines
-
Breaking화일약품, 100억원 규모 제3자배정 유상증자…파마앤바이오 신기술조합에 배정
1 more on this story · 1 outlets
- 화일약품, 100억원 유상증자…파마앤바이오 신기술조합에 제3자배정연합뉴스경제 · 17:11